Biosyent(TSE:RX)
CA$17.49-0.28 (-1.58%)
TSE:RX
Biosyent financials statements
CA$17.49
At close:-0.28 (-1.58%)
Want to see TSE:RX full AI Analyst Report?
Biosyent (RX) Ratios
56 Followers
Biosyent Ratios
TSE:RX's free cash flow for Q3 2026 was C$6.28M. For the 2026 fiscal year, TSE:RX's free cash flow was decreased by C$-21.93K and operating cash flow was C$6.31M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.51 | 4.53 | 6.48 | 6.49 | 8.24 |
| Quick Ratio | 4.63 | 3.54 | 5.42 | 5.70 | 7.70 |
| Cash Ratio | 2.81 | 2.24 | 1.44 | 1.38 | 4.36 |
| Solvency Ratio | 1.24 | 1.24 | 1.02 | 0.83 | 1.20 |
| Operating Cash Flow Ratio | 1.33 | 1.60 | 0.91 | 0.87 | 1.13 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 44.06 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | C$ 31.82M | C$ 18.11M | C$ 29.10M | C$ 30.02M | C$ 28.47M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.03 | 0.03 | 0.03 | 0.04 |
| Debt-to-Equity Ratio | 0.02 | 0.03 | 0.04 | 0.04 | 0.05 |
| Debt-to-Capital Ratio | 0.02 | 0.03 | 0.03 | 0.04 | 0.05 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.19 | 1.18 | 1.19 | 1.21 | 1.18 |
| Debt Service Coverage Ratio | 185.36 | 30.96 | 102.09 | 70.79 | 76.76 |
| Interest Coverage Ratio | 229.23 | 147.98 | 109.21 | 90.51 | 96.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.08 | 0.09 | 0.11 | 0.12 | 0.13 |
| Net Debt to EBITDA | -1.60 | -1.06 | -0.75 | -0.87 | -1.91 |
| Profitability Margins | |||||
| Gross Profit Margin | 74.59% | 79.52% | 81.03% | 81.85% | 79.10% |
| EBIT Margin | 26.28% | 28.09% | 27.23% | 25.00% | 28.59% |
| EBITDA Margin | 28.26% | 29.78% | 28.67% | 26.62% | 30.19% |
| Operating Profit Margin | 26.28% | 24.99% | 23.65% | 25.00% | 28.59% |
| Pretax Profit Margin | 27.94% | 27.93% | 27.01% | 26.61% | 29.28% |
| Net Profit Margin | 20.93% | 20.75% | 20.45% | 19.55% | 21.95% |
| Continuous Operations Profit Margin | 20.93% | 20.75% | 20.45% | 19.55% | 21.95% |
| Net Income Per EBT | 74.91% | 74.32% | 75.70% | 73.46% | 74.97% |
| EBT Per EBIT | 106.34% | 111.76% | 114.22% | 106.43% | 102.39% |
| Return on Assets (ROA) | 18.23% | 17.58% | 15.56% | 13.48% | 16.90% |
| Return on Equity (ROE) | 21.73% | 20.77% | 18.59% | 16.36% | 19.91% |
| Return on Capital Employed (ROCE) | 26.79% | 24.34% | 20.76% | 20.08% | 24.77% |
| Return on Invested Capital (ROIC) | 19.97% | 17.90% | 15.63% | 14.68% | 18.48% |
| Return on Tangible Assets | 20.19% | 20.02% | 16.00% | 13.89% | 17.31% |
| Earnings Yield | 6.29% | 5.70% | 6.04% | 6.34% | 5.99% |
| Efficiency Ratios | |||||
| Receivables Turnover | 9.49 | 11.70 | 8.91 | 7.64 | 8.92 |
| Payables Turnover | 1.78 | 1.79 | 1.18 | 1.00 | 1.68 |
| Inventory Turnover | 1.71 | 1.35 | 1.02 | 1.12 | 2.71 |
| Fixed Asset Turnover | 43.81 | 29.17 | 21.94 | 16.69 | 14.82 |
| Asset Turnover | 0.87 | 0.85 | 0.76 | 0.69 | 0.77 |
| Working Capital Turnover Ratio | 1.67 | 1.42 | 1.02 | 0.91 | 1.05 |
| Cash Conversion Cycle | 47.42 | 98.82 | 90.73 | 9.80 | -42.02 |
| Days of Sales Outstanding | 38.46 | 31.20 | 40.98 | 47.80 | 40.91 |
| Days of Inventory Outstanding | 214.04 | 271.05 | 359.04 | 326.68 | 134.54 |
| Days of Payables Outstanding | 205.09 | 203.44 | 309.29 | 364.68 | 217.47 |
| Operating Cycle | 252.51 | 302.25 | 400.02 | 374.48 | 175.44 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.85 | 0.75 | 0.42 | 0.40 | 0.37 |
| Free Cash Flow Per Share | 0.85 | 0.34 | 0.41 | 0.36 | 0.36 |
| Dividend Paid and CapEx Coverage Ratio | 4.17 | 1.28 | 2.42 | 4.93 | 50.17 |
| Capital Expenditure Coverage Ratio | 177.99 | 1.86 | 29.01 | 9.53 | 50.17 |
| Operating Cash Flow Coverage Ratio | 11.44 | 8.35 | 4.14 | 3.55 | 3.00 |
| Operating Cash Flow to Sales Ratio | 0.22 | 0.25 | 0.16 | 0.18 | 0.16 |
| Free Cash Flow Yield | 6.67% | 3.13% | 4.56% | 5.14% | 4.37% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 15.91 | 17.46 | 16.56 | 15.78 | 16.69 |
| Price-to-Sales (P/S) Ratio | 3.33 | 3.64 | 3.39 | 3.08 | 3.66 |
| Price-to-Book (P/B) Ratio | 3.46 | 3.64 | 3.08 | 2.58 | 3.32 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 14.99 | 31.91 | 21.91 | 19.44 | 22.88 |
| Price-to-Operating Cash Flow Ratio | 14.90 | 14.71 | 21.16 | 17.40 | 22.42 |
| Price-to-Earnings Growth (PEG) Ratio | 0.59 | 1.05 | 0.73 | -1.31 | 0.23 |
| Enterprise Value Multiple | 10.19 | 11.16 | 11.06 | 10.72 | 10.22 |
| Enterprise Value | 123.92M | 116.38M | 100.19M | 79.65M | 88.33M |
| EV to EBITDA | 10.19 | 11.16 | 11.06 | 10.72 | 10.22 |
| EV to Sales | 2.88 | 3.32 | 3.17 | 2.85 | 3.09 |
| EV to Free Cash Flow | 12.95 | 29.14 | 20.53 | 17.98 | 19.28 |
| EV to Operating Cash Flow | 12.88 | 13.43 | 19.82 | 16.10 | 18.90 |
| Tangible Book Value Per Share | 3.26 | 2.59 | 2.81 | 2.61 | 2.42 |
| Shareholders’ Equity Per Share | 3.68 | 3.02 | 2.91 | 2.71 | 2.49 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.25 | 0.26 | 0.24 | 0.27 | 0.25 |
| Revenue Per Share | 3.82 | 3.02 | 2.64 | 2.27 | 2.26 |
| Net Income Per Share | 0.80 | 0.63 | 0.54 | 0.44 | 0.50 |
| Tax Burden | 0.75 | 0.74 | 0.76 | 0.73 | 0.75 |
| Interest Burden | 1.06 | 0.99 | 0.99 | 1.06 | 1.02 |
| Research & Development to Revenue | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 |
| SG&A to Revenue | 0.46 | 0.50 | 0.31 | 0.32 | 0.16 |
| Stock-Based Compensation to Revenue | 0.01 | 0.02 | 0.02 | 0.02 | 0.01 |
| Income Quality | 1.07 | 1.19 | 0.78 | 0.91 | 0.74 |
Currency in CAD

